These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 17383435

  • 21. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalù AB.
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [Abstract] [Full Text] [Related]

  • 22. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB.
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract] [Full Text] [Related]

  • 23. Short-term study of infliximab treatment for Crohn's disease in China.
    Zheng JJ, Zhi P, Wang YM, Zhu F, Gu W, Xing YC, Zhou CL, Shen BW.
    J Dig Dis; 2011 Apr; 12(2):105-9. PubMed ID: 21401895
    [Abstract] [Full Text] [Related]

  • 24. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance.
    Francis G, Duggan A.
    Gastroenterology; 2008 Dec; 135(6):2156-7. PubMed ID: 19013168
    [No Abstract] [Full Text] [Related]

  • 25. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [Abstract] [Full Text] [Related]

  • 26. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ.
    Gastroenterology; 2003 Apr; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract] [Full Text] [Related]

  • 27. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 28. Australian Crohn's antibiotic study opens new horizons.
    Gitlin L, Biesecker J.
    Gastroenterology; 2007 Nov; 133(5):1743-4; author reply 1745-6. PubMed ID: 17983826
    [No Abstract] [Full Text] [Related]

  • 29. Immunogenicity of infliximab in Crohn's disease.
    Hanauer SB.
    N Engl J Med; 2003 May 22; 348(21):2155-6; author reply 2155-6. PubMed ID: 12761378
    [No Abstract] [Full Text] [Related]

  • 30. Medical management of Crohn's disease: a guide for radiologists.
    Helper DJ.
    Eur J Radiol; 2009 Mar 22; 69(3):371-4. PubMed ID: 19223133
    [Abstract] [Full Text] [Related]

  • 31. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J.
    Am J Gastroenterol; 2009 Mar 22; 104(3):760-7. PubMed ID: 19174781
    [Abstract] [Full Text] [Related]

  • 32. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct 20; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract] [Full Text] [Related]

  • 33. The great debate: stopping immunomodulators and biologics in Crohn's disease patients in remission.
    Hashash JG, Regueiro MD.
    Expert Rev Gastroenterol Hepatol; 2013 Aug 20; 7(6):501-3. PubMed ID: 23984997
    [No Abstract] [Full Text] [Related]

  • 34. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
    Tilg H, Knoflach P, Petritsch W, Vogelsang H, Reinisch W, Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH.
    Z Gastroenterol; 2004 Oct 20; 42(10):1256-63. PubMed ID: 15508068
    [No Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.
    Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A, Blank M, Johanns J, Lang Y, Markowitz J, Cohen S, Winter HS, Veereman-Wauters G, Ferry G, Baldassano R.
    Curr Med Res Opin; 2011 Mar 20; 27(3):651-62. PubMed ID: 21241207
    [Abstract] [Full Text] [Related]

  • 36. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study.
    Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ.
    Aliment Pharmacol Ther; 2006 Apr 15; 23(8):1127-36. PubMed ID: 16611273
    [Abstract] [Full Text] [Related]

  • 37. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
    Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M.
    Am J Gastroenterol; 2003 Dec 15; 98(12):2812-3. PubMed ID: 14687847
    [No Abstract] [Full Text] [Related]

  • 38. [Maintaining a remission].
    Fleig WE, German Society for Digestive and Metabolic Diseases.
    Z Gastroenterol; 2003 Jan 15; 41(1):36-42. PubMed ID: 12541172
    [No Abstract] [Full Text] [Related]

  • 39. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
    Veres G, Szabó D, Várkonyi A, Tari B, Polgár M, B Kovács J, Horváth A, Tomsits E, Tokodi I, Bodánszky H, Dezsofi A, Szakos E, Vass N, Ruszinkó V, Kovács M, Müller KE, Arató A.
    Orv Hetil; 2010 Jan 31; 151(5):179-83. PubMed ID: 20083466
    [Abstract] [Full Text] [Related]

  • 40. Remicade approved for children with Crohn's disease.
    FDA Consum; 2006 Jan 31; 40(4):6. PubMed ID: 17245830
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.